APO Research
Talk to an analyst

APO RESEARCH · REPORT

China PD-L1 and PIK3CA Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global China PD-L1 and PIK3CA Testing Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchChina PD-L1 and PIK3CA Testing Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal China PD-L1 and PIK3CA Testing Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal China PD-L1 and PIK3CA Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal China PD-L1 and PIK3CA Testing Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal China PD-L1 and PIK3CA Testing Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global China PD-L1 and PIK3CA Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for China PD-L1 and PIK3CA Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for China PD-L1 and PIK3CA Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for China PD-L1 and PIK3CA Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the China PD-L1 and PIK3CA Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the China PD-L1 and PIK3CA Testing market include Agilent Technologies, EntroGen, QIAGEN, Amoy Diagnostics, Roche and ACCB Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global China PD-L1 and PIK3CA Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of China PD-L1 and PIK3CA Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents China PD-L1 and PIK3CA Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global China PD-L1 and PIK3CA Testing market.

China PD-L1 and PIK3CA Testing Segment by Company

Agilent Technologies

EntroGen

QIAGEN

Amoy Diagnostics

Roche

ACCB Biotech

China PD-L1 and PIK3CA Testing Segment by Type

PD-L1 Testing

PIK3CA Testing

China PD-L1 and PIK3CA Testing Segment by Application

Hospital

Diagnostic Center

Others

China PD-L1 and PIK3CA Testing Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global China PD-L1 and PIK3CA Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the China PD-L1 and PIK3CA Testing key companies, revenue, market share, and recent developments.

3. To split the China PD-L1 and PIK3CA Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions China PD-L1 and PIK3CA Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify China PD-L1 and PIK3CA Testing significant trends, drivers, influence factors in global and regions.

6. To analyze China PD-L1 and PIK3CA Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global China PD-L1 and PIK3CA Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of China PD-L1 and PIK3CA Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of China PD-L1 and PIK3CA Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global China PD-L1 and PIK3CA Testing industry.

Chapter 3: Detailed analysis of China PD-L1 and PIK3CA Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of China PD-L1 and PIK3CA Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of China PD-L1 and PIK3CA Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. China PD-L1 and PIK3CA Testing Industry Trends Table 2. China PD-L1 and PIK3CA Testing Industry Drivers Table 3. China PD-L1 and PIK3CA Testing Industry Opportunities and Challenges Table 4. China PD-L1 and PIK3CA Testing Industry Restraints Table 5. Global China PD-L1 and PIK3CA Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global China PD-L1 and PIK3CA Testing Revenue Share by Company (2021-2026) Table 7. Global China PD-L1 and PIK3CA Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global China PD-L1 and PIK3CA Testing Key Company Manufacturing Base & Headquarters Table 9. Global China PD-L1 and PIK3CA Testing Company, Product Type & Application Table 10. Global China PD-L1 and PIK3CA Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global China PD-L1 and PIK3CA Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of PD-L1 Testing Table 15. Significant Companies of PIK3CA Testing Table 16. Global China PD-L1 and PIK3CA Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global China PD-L1 and PIK3CA Testing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global China PD-L1 and PIK3CA Testing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global China PD-L1 and PIK3CA Testing Sales Value Share by Type (2021-2026) Table 20. Global China PD-L1 and PIK3CA Testing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Diagnostic Center Table 23. Significant Companies of Others Table 24. Global China PD-L1 and PIK3CA Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global China PD-L1 and PIK3CA Testing Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global China PD-L1 and PIK3CA Testing Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global China PD-L1 and PIK3CA Testing Sales Value Share by Application (2021-2026) Table 28. Global China PD-L1 and PIK3CA Testing Sales Value Share by Application (2027-2032) Table 29. Global China PD-L1 and PIK3CA Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global China PD-L1 and PIK3CA Testing Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global China PD-L1 and PIK3CA Testing Sales Value Share by Region (2021-2026) Table 32. Global China PD-L1 and PIK3CA Testing Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global China PD-L1 and PIK3CA Testing Sales Value Share by Region (2027-2032) Table 34. Global China PD-L1 and PIK3CA Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global China PD-L1 and PIK3CA Testing Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global China PD-L1 and PIK3CA Testing Sales Value Market Share by Country (2021-2026) Table 37. Global China PD-L1 and PIK3CA Testing Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global China PD-L1 and PIK3CA Testing Sales Value Market Share by Country (2027-2032) Table 39. Agilent Technologies Company Information Table 40. Agilent Technologies Business Overview Table 41. Agilent Technologies China PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Agilent Technologies China PD-L1 and PIK3CA Testing Product Portfolio Table 43. Agilent Technologies Recent Development Table 44. EntroGen Company Information Table 45. EntroGen Business Overview Table 46. EntroGen China PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. EntroGen China PD-L1 and PIK3CA Testing Product Portfolio Table 48. EntroGen Recent Development Table 49. QIAGEN Company Information Table 50. QIAGEN Business Overview Table 51. QIAGEN China PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. QIAGEN China PD-L1 and PIK3CA Testing Product Portfolio Table 53. QIAGEN Recent Development Table 54. Amoy Diagnostics Company Information Table 55. Amoy Diagnostics Business Overview Table 56. Amoy Diagnostics China PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Amoy Diagnostics China PD-L1 and PIK3CA Testing Product Portfolio Table 58. Amoy Diagnostics Recent Development Table 59. Roche Company Information Table 60. Roche Business Overview Table 61. Roche China PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Roche China PD-L1 and PIK3CA Testing Product Portfolio Table 63. Roche Recent Development Table 64. ACCB Biotech Company Information Table 65. ACCB Biotech Business Overview Table 66. ACCB Biotech China PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. ACCB Biotech China PD-L1 and PIK3CA Testing Product Portfolio Table 68. ACCB Biotech Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. China PD-L1 and PIK3CA Testing Product Image Figure 2. Global China PD-L1 and PIK3CA Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global China PD-L1 and PIK3CA Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global China PD-L1 and PIK3CA Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. PD-L1 Testing Image Figure 8. PIK3CA Testing Image Figure 9. Global China PD-L1 and PIK3CA Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global China PD-L1 and PIK3CA Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global China PD-L1 and PIK3CA Testing Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Diagnostic Center Image Figure 14. Others Image Figure 15. Global China PD-L1 and PIK3CA Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global China PD-L1 and PIK3CA Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global China PD-L1 and PIK3CA Testing Sales Value Share by Application (2021-2032) Figure 18. Global China PD-L1 and PIK3CA Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global China PD-L1 and PIK3CA Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America China PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 21. North America China PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe China PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 23. Europe China PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific China PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific China PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America China PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 27. South America China PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa China PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa China PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • PD-L1 Testing
  • PIK3CA Testing
Applications
  • Hospital
  • Diagnostic Center
  • Others
Companies covered
  • Agilent Technologies
  • EntroGen
  • QIAGEN
  • Amoy Diagnostics
  • Roche
  • ACCB Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global China PD-L1 and PIK3CA Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global China PD-L1 and PIK3CA Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 China PD-L1 and PIK3CA Testing Market Dynamics
  1. 2.1 China PD-L1 and PIK3CA Testing Industry Trends
  2. 2.2 China PD-L1 and PIK3CA Testing Industry Drivers
  3. 2.3 China PD-L1 and PIK3CA Testing Industry Opportunities and Challenges
  4. 2.4 China PD-L1 and PIK3CA Testing Industry Restraints
3 China PD-L1 and PIK3CA Testing Market by Company
  1. 3.1 Global China PD-L1 and PIK3CA Testing Company Revenue Ranking in 2025
  2. 3.2 Global China PD-L1 and PIK3CA Testing Revenue by Company (2021-2026)
  3. 3.3 Global China PD-L1 and PIK3CA Testing Company Ranking (2024-2026)
  4. 3.4 Global China PD-L1 and PIK3CA Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global China PD-L1 and PIK3CA Testing Company Product Type and Application
  6. 3.6 Global China PD-L1 and PIK3CA Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global China PD-L1 and PIK3CA Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 China PD-L1 and PIK3CA Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 China PD-L1 and PIK3CA Testing Market by Type
  1. 4.1 China PD-L1 and PIK3CA Testing Type Introduction
  2. 4.1.1 PD-L1 Testing
  3. 4.1.2 PIK3CA Testing
  4. 4.2 Global China PD-L1 and PIK3CA Testing Sales Value by Type
  5. 4.2.1 Global China PD-L1 and PIK3CA Testing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global China PD-L1 and PIK3CA Testing Sales Value by Type (2021-2032)
  7. 4.2.3 Global China PD-L1 and PIK3CA Testing Sales Value Share by Type (2021-2032)
5 China PD-L1 and PIK3CA Testing Market by Application
  1. 5.1 China PD-L1 and PIK3CA Testing Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Diagnostic Center
  4. 5.1.3 Others
  5. 5.2 Global China PD-L1 and PIK3CA Testing Sales Value by Application
  6. 5.2.1 Global China PD-L1 and PIK3CA Testing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global China PD-L1 and PIK3CA Testing Sales Value by Application (2021-2032)
  8. 5.2.3 Global China PD-L1 and PIK3CA Testing Sales Value Share by Application (2021-2032)
6 China PD-L1 and PIK3CA Testing Regional Value Analysis
  1. 6.1 Global China PD-L1 and PIK3CA Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global China PD-L1 and PIK3CA Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global China PD-L1 and PIK3CA Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global China PD-L1 and PIK3CA Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America China PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  7. 6.3.2 North America China PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe China PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  10. 6.4.2 Europe China PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific China PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific China PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America China PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  16. 6.6.2 South America China PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa China PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa China PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
7 China PD-L1 and PIK3CA Testing Country-level Value Analysis
  1. 7.1 Global China PD-L1 and PIK3CA Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global China PD-L1 and PIK3CA Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global China PD-L1 and PIK3CA Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global China PD-L1 and PIK3CA Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilent Technologies
  2. 8.1.1 Agilent Technologies Company Information
  3. 8.1.2 Agilent Technologies Business Overview
  4. 8.1.3 Agilent Technologies China PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilent Technologies China PD-L1 and PIK3CA Testing Product Portfolio
  6. 8.1.5 Agilent Technologies Recent Developments
  7. 8.2 EntroGen
  8. 8.2.1 EntroGen Company Information
  9. 8.2.2 EntroGen Business Overview
  10. 8.2.3 EntroGen China PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 EntroGen China PD-L1 and PIK3CA Testing Product Portfolio
  12. 8.2.5 EntroGen Recent Developments
  13. 8.3 QIAGEN
  14. 8.3.1 QIAGEN Company Information
  15. 8.3.2 QIAGEN Business Overview
  16. 8.3.3 QIAGEN China PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 QIAGEN China PD-L1 and PIK3CA Testing Product Portfolio
  18. 8.3.5 QIAGEN Recent Developments
  19. 8.4 Amoy Diagnostics
  20. 8.4.1 Amoy Diagnostics Company Information
  21. 8.4.2 Amoy Diagnostics Business Overview
  22. 8.4.3 Amoy Diagnostics China PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Amoy Diagnostics China PD-L1 and PIK3CA Testing Product Portfolio
  24. 8.4.5 Amoy Diagnostics Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche China PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche China PD-L1 and PIK3CA Testing Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 ACCB Biotech
  32. 8.6.1 ACCB Biotech Company Information
  33. 8.6.2 ACCB Biotech Business Overview
  34. 8.6.3 ACCB Biotech China PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ACCB Biotech China PD-L1 and PIK3CA Testing Product Portfolio
  36. 8.6.5 ACCB Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst